ID1463 anakinra ACD to PM for consultation (online commenting version) [noACIC].docx
Closed for comments This consultation ended on at Request commenting lead permission
2 Information about anakinra
Marketing authorisation indication
2.1 Anakinra (Kineret, Sobi) is 'indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids'. It can be given alone or with other anti-inflammatory drugs and disease-modifying antirheumatic drugs.
Dosage in the marketing authorisation
2.2 The dosage schedule is available in the summary of product characteristics.
Price
2.3 The cost for 7 prefilled injections (each containing 100 mg anakinra per 0.67 ml) is £183.61, excluding VAT (BNF, accessed December 2020). The average cost of 1 year of treatment is £9,580.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation